Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports

Francesca Romana Ponziani, Massimo Siciliano, Raffaella Lionetti, Caterina Pasquazzi, Laura Gianserra, Gianpiero D'Offizi, Antonio Gasbarrini, Maurizio Pompili

Research output: Contribution to journalArticle

Abstract

Hepatitis C virus infection is common among patients on hemodialysis therapy and is an important cause of morbidity and mortality. We investigated the safety and effectiveness of a paritaprevir/ritonavir/ombitasvir/dasabuvir regimen in a group of 10 patients on hemodialysis therapy with genotype 1a, 1b, or 4 hepatitis C virus infection who had predictors of unfavorable response, such as compensated cirrhosis (7 patients) or advanced fibrosis and failure of previous therapy (3 patients). The treatment, with or without ribavirin, was administered daily for 12 or 24 weeks. Clinical and virologic assessment was performed every 4 weeks during the treatment and at posttreatment weeks 4 and 12. All patients achieved a sustained virologic response at posttreatment week 12. 80% of patients reported at least one adverse event: fatigue and anemia of mild intensity were the most common; a single episode of moderate liver decompensation was observed. The paritaprevir/ritonavir/ombitasvir/dasabuvir antiviral regimen is effective and well tolerated in genotype 1 or 4 hepatitis C virus–infected patients on hemodialysis therapy with compensated cirrhosis and/or failure of previous treatments.

Original languageEnglish
Pages (from-to)297-300
Number of pages4
JournalAmerican Journal of Kidney Diseases
Volume70
Issue number2
DOIs
Publication statusPublished - Aug 1 2017

Fingerprint

Ritonavir
Virus Diseases
Hepacivirus
Liver Cirrhosis
Renal Dialysis
Fibrosis
Therapeutics
Genotype
Ribavirin
Hepatitis C
ABT-450
ABT-267
ABT-333
Treatment Failure
Antiviral Agents
Fatigue
Anemia
Morbidity
Safety
Mortality

Keywords

  • advanced liver fibrosis
  • adverse event
  • antiviral regimen
  • case reports
  • cirrhosis
  • dasabuvir
  • decreased kidney function
  • direct-acting antivirals
  • end-stage renal disease (ESRD)
  • HCV genotype
  • hemodialysis
  • Hepatitis C virus (HCV)
  • ombitasvir
  • paritaprevir
  • ribavirin
  • ritonavir
  • sustained virological response

ASJC Scopus subject areas

  • Nephrology

Cite this

Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis : Case Reports. / Ponziani, Francesca Romana; Siciliano, Massimo; Lionetti, Raffaella; Pasquazzi, Caterina; Gianserra, Laura; D'Offizi, Gianpiero; Gasbarrini, Antonio; Pompili, Maurizio.

In: American Journal of Kidney Diseases, Vol. 70, No. 2, 01.08.2017, p. 297-300.

Research output: Contribution to journalArticle

Ponziani, Francesca Romana ; Siciliano, Massimo ; Lionetti, Raffaella ; Pasquazzi, Caterina ; Gianserra, Laura ; D'Offizi, Gianpiero ; Gasbarrini, Antonio ; Pompili, Maurizio. / Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis : Case Reports. In: American Journal of Kidney Diseases. 2017 ; Vol. 70, No. 2. pp. 297-300.
@article{2f0e0868cbb54f39858a2a82a3359fe5,
title = "Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports",
abstract = "Hepatitis C virus infection is common among patients on hemodialysis therapy and is an important cause of morbidity and mortality. We investigated the safety and effectiveness of a paritaprevir/ritonavir/ombitasvir/dasabuvir regimen in a group of 10 patients on hemodialysis therapy with genotype 1a, 1b, or 4 hepatitis C virus infection who had predictors of unfavorable response, such as compensated cirrhosis (7 patients) or advanced fibrosis and failure of previous therapy (3 patients). The treatment, with or without ribavirin, was administered daily for 12 or 24 weeks. Clinical and virologic assessment was performed every 4 weeks during the treatment and at posttreatment weeks 4 and 12. All patients achieved a sustained virologic response at posttreatment week 12. 80{\%} of patients reported at least one adverse event: fatigue and anemia of mild intensity were the most common; a single episode of moderate liver decompensation was observed. The paritaprevir/ritonavir/ombitasvir/dasabuvir antiviral regimen is effective and well tolerated in genotype 1 or 4 hepatitis C virus–infected patients on hemodialysis therapy with compensated cirrhosis and/or failure of previous treatments.",
keywords = "advanced liver fibrosis, adverse event, antiviral regimen, case reports, cirrhosis, dasabuvir, decreased kidney function, direct-acting antivirals, end-stage renal disease (ESRD), HCV genotype, hemodialysis, Hepatitis C virus (HCV), ombitasvir, paritaprevir, ribavirin, ritonavir, sustained virological response",
author = "Ponziani, {Francesca Romana} and Massimo Siciliano and Raffaella Lionetti and Caterina Pasquazzi and Laura Gianserra and Gianpiero D'Offizi and Antonio Gasbarrini and Maurizio Pompili",
year = "2017",
month = "8",
day = "1",
doi = "10.1053/j.ajkd.2017.01.037",
language = "English",
volume = "70",
pages = "297--300",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis

T2 - Case Reports

AU - Ponziani, Francesca Romana

AU - Siciliano, Massimo

AU - Lionetti, Raffaella

AU - Pasquazzi, Caterina

AU - Gianserra, Laura

AU - D'Offizi, Gianpiero

AU - Gasbarrini, Antonio

AU - Pompili, Maurizio

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Hepatitis C virus infection is common among patients on hemodialysis therapy and is an important cause of morbidity and mortality. We investigated the safety and effectiveness of a paritaprevir/ritonavir/ombitasvir/dasabuvir regimen in a group of 10 patients on hemodialysis therapy with genotype 1a, 1b, or 4 hepatitis C virus infection who had predictors of unfavorable response, such as compensated cirrhosis (7 patients) or advanced fibrosis and failure of previous therapy (3 patients). The treatment, with or without ribavirin, was administered daily for 12 or 24 weeks. Clinical and virologic assessment was performed every 4 weeks during the treatment and at posttreatment weeks 4 and 12. All patients achieved a sustained virologic response at posttreatment week 12. 80% of patients reported at least one adverse event: fatigue and anemia of mild intensity were the most common; a single episode of moderate liver decompensation was observed. The paritaprevir/ritonavir/ombitasvir/dasabuvir antiviral regimen is effective and well tolerated in genotype 1 or 4 hepatitis C virus–infected patients on hemodialysis therapy with compensated cirrhosis and/or failure of previous treatments.

AB - Hepatitis C virus infection is common among patients on hemodialysis therapy and is an important cause of morbidity and mortality. We investigated the safety and effectiveness of a paritaprevir/ritonavir/ombitasvir/dasabuvir regimen in a group of 10 patients on hemodialysis therapy with genotype 1a, 1b, or 4 hepatitis C virus infection who had predictors of unfavorable response, such as compensated cirrhosis (7 patients) or advanced fibrosis and failure of previous therapy (3 patients). The treatment, with or without ribavirin, was administered daily for 12 or 24 weeks. Clinical and virologic assessment was performed every 4 weeks during the treatment and at posttreatment weeks 4 and 12. All patients achieved a sustained virologic response at posttreatment week 12. 80% of patients reported at least one adverse event: fatigue and anemia of mild intensity were the most common; a single episode of moderate liver decompensation was observed. The paritaprevir/ritonavir/ombitasvir/dasabuvir antiviral regimen is effective and well tolerated in genotype 1 or 4 hepatitis C virus–infected patients on hemodialysis therapy with compensated cirrhosis and/or failure of previous treatments.

KW - advanced liver fibrosis

KW - adverse event

KW - antiviral regimen

KW - case reports

KW - cirrhosis

KW - dasabuvir

KW - decreased kidney function

KW - direct-acting antivirals

KW - end-stage renal disease (ESRD)

KW - HCV genotype

KW - hemodialysis

KW - Hepatitis C virus (HCV)

KW - ombitasvir

KW - paritaprevir

KW - ribavirin

KW - ritonavir

KW - sustained virological response

UR - http://www.scopus.com/inward/record.url?scp=85014069713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014069713&partnerID=8YFLogxK

U2 - 10.1053/j.ajkd.2017.01.037

DO - 10.1053/j.ajkd.2017.01.037

M3 - Article

C2 - 28258770

AN - SCOPUS:85014069713

VL - 70

SP - 297

EP - 300

JO - American Journal of Kidney Diseases

JF - American Journal of Kidney Diseases

SN - 0272-6386

IS - 2

ER -